



SCSHP Annual Meeting

March 3-4, 2022

Final

Thursday, March 3, 2022	
8:00 am – 8:30 am	Meeting Opening & Intro of Keynote Speaker
8:30 am – 9:30 am	Keynote Speaker: Jason Mills (no ACPE credit awarded for this presentation)
9:30 am - 10:30 am	<p>Go with the Flozins: Expanded Role of SGLT2 Inhibitors for Chronic Kidney Disease Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM; Clinical Pharmacist, Spartanburg Regional Healthcare <i>ACPE UAN 0062-9999-22-065-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Explain the mechanism of SGLT2i for CKD 2. Critically evaluate the published literature of renal outcomes regarding SGLT2i for CKD 3. Formulate a person-centered treatment plan with monitoring parameters for CKD <p><i>At the completion of this activity, the pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Explain the mechanism of SGLT2i for CKD 2. Summarize a potential benefit and risk of SGLT2i on renal outcomes for CKD 3. Determine appropriate counseling points with a SGLT2i for a person with CKD
10:30 am – 11:00 am	Break
11:00 am - 12:00 pm	<p>Professional Continuous Glucose Monitors in Primary Care Aly York, PharmD & Lawrence Bean, PharmD; PGY1 Outpatient Pharmacy Residents, Prisma Health Richland <i>ACPE UAN 0062-9999-22-066-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Distinguish between professional and personal CGMs 2. Describe the characteristics of the different professional CGMs on the market 3. Define the role of a pharmacist in the implementation and interpretation of professional CGMs 4. Evaluate the effectiveness of professional CGMs in diabetes management
12:00 pm - 1:00 pm	<p>2022 Clinical Pharmacy Challenge: Part 1 <i>ACPE UAN 0062-9999-22-067-L01-P/T, 1.0 contact hours, knowledge-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Recall pharmacy trivia related to pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenomics, clinical pharmacy history, biostatistics, and health outcomes 2. Summarize clinical knowledge in response to a case vignette using supporting laboratory, physical examination, and medical history information 3. Discuss numerous drug therapy and specialty areas through response to pharmacotherapy questions
1:00 pm – 2:00 pm	Lunch
2:00 pm – 3:00 pm	<p>2022 Platform Presentations Gadison Quick, PharmD; PGY2 Internal Medicine Pharmacy Resident Carly Huggins, PharmD Candidate 2022; University of South Carolina College of Pharmacy Rachel Robinson, PharmD Candidate; Presbyterian College School of Pharmacy <i>ACPE UAN 0062-9999-22-068-L01-P/T, 1.0 contact hours, knowledge-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Discuss emerging research outcomes from throughout the state of South Carolina 2. Recognize novel ideas for research and quality initiative projects in your pharmacy practice areas 3. Review pivotal results from local investigations across the state of South Carolina

3:00 pm – 3:30 pm	Break
3:30 pm – 4:00 pm	2022 Clinical Pharmacy Challenge: Part 2 <i>ACPE UAN 0062-9999-22-069-L01-P/T, 0.50 contact hours, knowledge-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i> <ol style="list-style-type: none">1. Recall pharmacy trivia related to pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenomics, clinical pharmacy history, biostatistics, and health outcomes2. Summarize clinical knowledge in response to a case vignette using supporting laboratory, physical examination, and medical history information3. Discuss numerous drug therapy and specialty areas through response to pharmacotherapy questions
4:00 pm – 5:00 pm	Poster Presentations (no ACPE credit awarded)

Friday, March 4, 2022

8:00 am	Meeting Opening
8:00 am – 9:00 am	<p>The Pharmacologic Management of HFpEF: Is there a change of heart? Sanyia Khan, PharmD; CVICU Clinical Specialist, Spartanburg Medical Center Katy Wolfe, PharmD; PGY1 Pharmacy Resident, Spartanburg Medical Center <i>ACPE UAN 0062-9999-22-070-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Differentiate between the types of heart failure (HF) 2. Describe the pathophysiology of HF 3. Examine the historical pharmacologic management of Heart failure with preserved ejection fraction (HFpEF) 4. Analyze recent primary literature related to the management of HFpEF 5. Develop a treatment plan with monitoring when given a patient scenario with HFpEF
9:00 am – 10:00 am	<p>Hit Me With Your Best Shot: Cabotegravir/Rilpivirine Long-acting Injectable Vivian Tsai, PharmD & Morgan Pizzuti, PharmD; PGY2 Infectious Diseases Pharmacy Residents, Prisma Health Richland – University of South Carolina <i>ACPE UAN 0062-9999-22-071-L02-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Summarize the efficacy and safety of cabotegravir/rilpivirine long-acting injectable for HIV treatment 2. Describe the workflow of implementing cabotegravir/rilpivirine long-acting injectable into real-world practice 3. Apply current recommendations regarding cabotegravir/rilpivirine long-acting injectable for the treatment of HIV
10:00 am – 10:15 am	Break
10:15 am – 11:15 am	<p>Don't Sugarcoat It: Overview and Updates on Diabetic Ketoacidosis Amanda Guffey, PharmD, BCCCP, BCPS; Clinical Pharmacist – Critical Care, Lexington Medical Center <i>ACPE UAN 0062-9999-22-072-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe the pathophysiology and clinical presentation of diabetic ketoacidosis (DKA) 2. Identify electrolyte disturbances often associated with DKA 3. Review treatment guidelines for DKA 4. Evaluate recent literature for selection of IV fluids in treatment of DKA 5. Define euglycemic DKA and the risks associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors <p><i>At the completion of this activity, the pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe the presentation of diabetic ketoacidosis (DKA) 2. Identify electrolyte disturbances often associated with DKA 3. Recognize therapeutic options for DKA
11:15 am – 12:15 pm	<p>Antiplatelet Optimization in Acute Coronary Syndromes Ashley Costello, PharmD, BCPS; Clinical Pharmacist, Self Regional Healthcare <i>ACPE UAN 0062-9999-22-073-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe the role of antiplatelets in the pathophysiology of coronary artery disease 2. Assess patient-specific characteristics, including ischemic and bleeding risks, to evaluate selection of antiplatelet management 3. Examine guidelines and clinical trial recommendations for P2Y12 inhibitor selection, duration, and dose in acute coronary syndromes 4. Develop an individualized, patient-center approach regarding antiplatelet management in coronary artery disease <p><i>At the completion of this activity, the pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe the role of antiplatelets in the pathophysiology of coronary artery disease 2. Recognize patient-specific characteristics that impact the selection of antiplatelet management 3. Discuss the role of shared decision making in the treatment of coronary artery disease

12:15 pm – 12:45 pm	<p>An Evidence-Based Approach to Double-Covering Pseudomonas (Or Not) Michael K. Shaw, PharmD; PGY1 Pharmacy Resident, Bon Secours St. Francis Downtown <i>ACPE UAN 0062-9999-22-074-L01-P/T, 0.50 contact hours, knowledge-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Review the microbiology, pathogenicity, and common mechanisms of resistance of Pseudomonas aeruginosa 2. List the typical antibiotics utilized to treat Pseudomonas infections 3. Evaluate the guidelines and other literature surrounding the treatment of Pseudomonas infections
12:45 pm – 1:30 pm	Lunch
1:30 pm – 2:30 pm	<p>The Path of Most Resistance: Where New Antimicrobial Agents Fit Into Practice Kelli R. Keats, PharmD, MPA, BCCCP; Critical Care Pharmacist – Medical ICU, Augusta University Medical Center <i>ACPE UAN 0062-9999-22-075-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe mechanisms of action and mechanisms of resistance to new antimicrobial agents including eravacycline, imipenem/cilastatin/relebactam, and cefiderocol 2. Evaluate in vitro literature for these agents as well as clinical trials 3. Select an antimicrobial agent based on resistance patterns, type of infection, and strength of clinical evidence <p><i>At the completion of this activity, the pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Recall the mechanisms of action and mechanisms of resistance to new antimicrobial agents 2. Recognize pharmacologic management strategies for resistant microbial infections
2:30 pm – 3:30 pm	<p>Reverse, Reverse! Antithrombotic Reversal Overview Katrina Phelps, PharmD; PGY1 Pharmacy Resident, Bon Secours St. Francis Downtown <i>ACPE UAN 0062-9999-22-076-L01-P/T, 1.0 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist and pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Evaluate the difference between major and non-major bleeding 2. Summarize current pharmacological interventions for antithrombotic reversal 3. Demonstrate understanding of antithrombotic reversal agent mechanisms of action 4. Review literature regarding controversies related to antithrombotic reversal
3:30 pm – 4:00 pm	Break
4:00 pm – 5:30 pm	<p>Let's Put Our Heads Together: A Debate on Acute Ischemic Stroke Management Trey Wingerson, PharmD; Assistant Professor of Pharmacy Practice, Presbyterian College School of Pharmacy Jimmy Pruitt, PharmD, BCPS, BCCCP; Emergency Medicine Clinical Pharmacy Specialist, Medical University of South Carolina <i>ACPE UAN 0062-9999-22-077-L01-P/T, 1.50 contact hours, application-based activity</i> <i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Compare and contrast eligibility criteria for thrombolytic therapy in acute ischemic stroke patients on the basis of emerging literature 2. Interpret the role and supporting evidence behind tenecteplase as an alternative to traditional thrombolytic treatment of stroke 3. Describe endovascular treatments for ischemic stroke, indications for use, eligibility of patients, and the concomitant use of thrombolytics 4. Develop treatment recommendations incorporating appropriate diagnostic modalities for a patient presenting with stroke-like symptoms <p><i>At the completion of this activity, the pharmacy technician will be able to:</i></p> <ol style="list-style-type: none"> 1. List common eligibility criteria for thrombolytic therapy in acute ischemic stroke 2. Describe the dosing and administration of tenecteplase for stroke treatment 3. Recognize non-pharmacologic treatments for ischemic stroke and the role for thrombolysis in patients undergoing endovascular therapies 4. Outline treatment recommendations for the management of acute ischemic stroke
5:30 pm	Adjournment and Evaluations



CONTINUING EDUCATION ACCREDITATION INFORMATION: The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The target audience for these continuing education activities is pharmacists and pharmacy technicians who are engaged in health-systems pharmacy practice. Please see each session for CE available for pharmacists and/or technicians, faculty information, ACPE UANs, learning objectives, and CEU designations. Sessions shaded in gray are not CE-accredited sessions.



To claim CE credit, participants must attend sessions in their entirety (no partial credit will be awarded for attendance at a portion of a session) and must participate in all active learning activities and learning assessments through the virtual platform. In order to have CPE credit reported to the NABP CPE Monitor, participants must have their virtual attendance verified and must follow the “Instructions to Claim Credit” which will be provided to participants. This includes completing program and speaker evaluations at <http://cop.sc.learningexpresssce.com> within 30 days and providing the correct NABP e-Profile ID and day/month of birth upon registration. Any credit not claimed within 60 days of the live event will be rejected by the NABP CPE Monitor. Please contact CE@cop.sc.edu or 803-777-9979 with any questions.

REGISTRATION AND FEES: Please visit <https://scshp.com/meetinginfo.php> to view all information regarding registration fees and to register for the meeting.